FDA APPROVES NEW ADD-ON DRUG TO TREAT OFF EPISODES IN ADULTS WITH PARKINSON’S DISEASE

-



Istradefylline (Nourianz, Kyowa Kirin) tablets have been approved by the US Food and Drug Administration (FDA) as add-on treatment to levodopa/carbidopa in adults who have Parkinson’s disease (PD) experiencing “off” episodes. 


Eric Bastings, M.D., acting director of the Division of Neurology Products in the FDA’s Centre for Drug Evaluation and Research said “Parkinson’s disease is a debilitating condition that profoundly impacts patients’ lives.”

Istradefylline is a selective adenosine A2A receptor antagonist. When treated on ‘off’ episodes in patients with PD taking levodopa/carbidopa its effectiveness was shown in four 12-week, placebo-controlled clinical studies that included a total of 1143 participants.

According to all the four studies, it reports that the addition of istradefylline leads to a statistically significant decrease from baseline in daily “off” time relative to placebo add-on, the FDA stated in a news release.

Dyskinesia, dizziness, constipation, nausea, hallucination, and insomnia were the most common adverse reactions observed in patients who consumed istradefylline. Patients should be monitored for the development of dyskinesia or exacerbation of existing dyskinesia. The FDA advises considering reducing the dose or stopping the drug usage if hallucinations, psychotic behaviour, or impulsive/compulsive behaviour occurs.

PD is the second most common neurodegenerative disorder in the United States after Alzheimer’s disease according to the National Institutes of Health. 50,000 Americans are estimated to be diagnosed with PD each year, and about 1 million Americans have the condition.


Comments

Post a Comment

Popular posts from this blog

Introduction to Regulatory Affairs & Explanation of terms related to Regulatory Affairs

-
Introduction to Regulatory Affairs What is Regulatory Affairs? Regulatory Affairs is a profession within regulated industries namely-pharmaceuticals, medical devices, energy and banking . It has specific meaning within healthcare industries namely- pharmaceuticals, medical devices, biologics and functional foods. (In this blog I am going to deal about Regulatory Affairs related to pharmaceuticals meant for human use). Regulatory Affairs in the pharma industry may be defined as " The interface between the pharmaceutical company and the regulatory agencies across the world. "   In the above presentation, I am conveying the fact that -among all the departments of a pharma company Regulatory Affairs Department acts as the interface between the pharmaceutical company and the regulatory agencies across the world. Regulatory agency in the present context may be defined as " The competent government agency which is responsible for ensuring that medici
Read more

GAP or Findings in Regulatory Compliance

-
Image
Gap Analysis for Regulatory Compliance Gap analysis is an effective tool to determine the deficiencies in implementation of any procedure or regulatory guidance. If you are preparing for any regulatory inspection then gap analysis can help in compliance with regulatory guidelines. A comparison between the regulatory guidance and current practices is known as gap analysis. Gap analysis should be done for all SOPs, validation procedures and other activities to find out the possibilities of improvement. The room for improvement is identified by gap analysis. Therefore, make the checklists of the document you want to analyze and then check the actual working against the checklist. Gap analysis should also be done for regulatory guidelines like data integrity, risk assessment, good manufacturing practices, good laboratory practices, good documentation practices, good distribution practices etc to eliminate the possible non-compliances. Gap analysis may be carried out for specifi
Read more

Artificial Intelligence in the Medical Robotics Industry – Current Applications

-
AI applications for healthcare are becoming more common for white-collar automation and diagnostics . However, medical robotics is an area that may be marginally underdeveloped. This is likely because of regulations concerning automated surgery. In this article, I cover how AI software is finding its way into medical robotics now and how it might in the future with more investment and when the density of AI talent at medical robotics companies increases. Specifically, we explore: AI for Medical Robotics – What’s Possible, and What’s Being Used by healthcare clients right now. We found little to no case studies showing a health network or hospital’s success with AI-based medical robotics. The State of AI at Medical Robotics Vendors – the AI talent at medical robotics companies and a discussion of how to vet a vendor on whether or not its software is truly leveraging AI We begin our exploration of AI applications for medical robotics with an overview of the po
Read more